- MGC Pharmaceuticals (MXC) receives study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial
- The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19
- Once completed, the trial will provide the data needed to plan future regulatory pathways to register CimetrA as a drug
- CimetrA is MGC’s natural, immune-modulation formula that is made up of vitamin C and herbal extracts used to treat anti-inflammatory illnesses
- MGC Pharma is trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST
MGC Pharmaceuticals (MXC) has been granted study and import approvals from the South African Health Products Regulatory Authority for the Phase IIb CimetrA trial.
The trial will aim to target the effects of viral infections with inflammatory complications in patients with moderate COVID-19.
It will determine the most effective dosage concentrations of the active ingredients and collect data to further validate CimetrA’s anti-inflammatory and immune-modulatory effects.
Once completed, the trial will provide further data for claims on the product as an investigational medical product and will provide data needed to plan future regulatory pathways to register CimetrA as a drug.
CimetrA is made up of artemisinin, a drug from a fern-like plant that is used against malaria, and curcumin, a chemical that aids in anti-inflammatory and antioxidants.
It is then mixed with vitamin C and boswellia serrata, a herbal extract used to treat inflammatory illnesses.
It can come in either a solid or a liquid form and has antioxidant, anti-inflammatory and immuno-modulating properties.
“With COVID-19 cases once again on the rise, the extension of the CimetrA dosage trial into South Africa could not be more important,” Co-Founder and Managing Director Roby Zomer commented.
“Clinical trials to date have demonstrated the efficacy of CimetrA against COVID-19, so it is crucial that we are able to complete the dosage trials in Israel and now South Africa as quickly as possible to we can move to the next stage of the clinical pipeline and treat those suffering from the effects of the cytokine storm and ‘long COVID’ more effectively.”
MGC Pharma was trading 11.1 per cent higher on the market at 2 cents at 2:52 pm AEST.